The impact of underlying diseases-related drugs on the chronic kidney disease-associated pruritus in hemodialysis patients.
Amiodarone
atorvastatin
chronic kidney disease
hemodialysis
pruritus
valsartan
Journal
Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences
ISSN: 1735-1995
Titre abrégé: J Res Med Sci
Pays: India
ID NLM: 101235599
Informations de publication
Date de publication:
2022
2022
Historique:
received:
20
07
2022
revised:
05
03
2022
accepted:
20
06
2022
entrez:
23
1
2023
pubmed:
24
1
2023
medline:
24
1
2023
Statut:
epublish
Résumé
Uremic pruritus or chronic kidney disease-associated pruritus (CKD-aP) is a frequent compromising symptom in end-stage renal disease. Despite the little attention paid to drugs used among hemodialysis (HD) patients, investigating medications used in this population of patients and examining the status of CKD-aP may lead to the identification of medications that improve or worsen the pruritus condition. We aimed to assess the role of underlying diseases-related drugs on CKD-aP in HD patients. We performed a case - control study on HD patients aged over 18 years old. The demographic data and clinical parameters including HD parameters, drug history, dermatologic assessments, and laboratory examination were assessed. We compared 128 patients with CKD-aP as cases and 109 patients without CKD-aP as controls. Cases were on the longer course of dialysis (44.69 ± 43.24 months for cases vs. 38.87 ± 50.73 months for controls; Atorvastatin was associated with decreased frequencies of CKD-aP among HD patients in our study. This knowledge may guide further clinical trials to evaluate atorvastatin's immunomodulatory and anti-inflammatory effects on the CKD-aP in HD populations.
Sections du résumé
Background
UNASSIGNED
Uremic pruritus or chronic kidney disease-associated pruritus (CKD-aP) is a frequent compromising symptom in end-stage renal disease. Despite the little attention paid to drugs used among hemodialysis (HD) patients, investigating medications used in this population of patients and examining the status of CKD-aP may lead to the identification of medications that improve or worsen the pruritus condition. We aimed to assess the role of underlying diseases-related drugs on CKD-aP in HD patients.
Materials and Methods
UNASSIGNED
We performed a case - control study on HD patients aged over 18 years old. The demographic data and clinical parameters including HD parameters, drug history, dermatologic assessments, and laboratory examination were assessed.
Results
UNASSIGNED
We compared 128 patients with CKD-aP as cases and 109 patients without CKD-aP as controls. Cases were on the longer course of dialysis (44.69 ± 43.24 months for cases vs. 38.87 ± 50.73 months for controls;
Conclusion
UNASSIGNED
Atorvastatin was associated with decreased frequencies of CKD-aP among HD patients in our study. This knowledge may guide further clinical trials to evaluate atorvastatin's immunomodulatory and anti-inflammatory effects on the CKD-aP in HD populations.
Identifiants
pubmed: 36685022
doi: 10.4103/jrms.jrms_633_21
pii: JRMS-27-86
pmc: PMC9854926
doi:
Types de publication
Journal Article
Langues
eng
Pagination
86Informations de copyright
Copyright: © 2022 Journal of Research in Medical Sciences.
Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
Qual Life Res. 2012 May;21(4):603-12
pubmed: 21744033
Kidney Int Rep. 2020 May 08;5(9):1387-1402
pubmed: 32954065
J Exp Med. 2006 Feb 20;203(2):401-12
pubmed: 16476765
Int J Dermatol. 2019 Mar;58(3):273-278
pubmed: 30039870
Immunology. 2018 May;154(1):69-75
pubmed: 29392731
Am J Kidney Dis. 2007 Jul;50(1):11-20
pubmed: 17591521
Cochrane Database Syst Rev. 2005 Oct 19;(4):CD003697
pubmed: 16235336
Vasc Health Risk Manag. 2006;2(1):87-93
pubmed: 17319473
Clin J Am Soc Nephrol. 2008 Sep;3(5):1526-33
pubmed: 18701615
Clin Nephrol. 2006 Sep;66(3):184-91
pubmed: 16995341
Mol Med Rep. 2017 Nov;16(5):6109-6115
pubmed: 28849160
Indian J Nephrol. 2016 Nov-Dec;26(6):398-404
pubmed: 27942169
Adv Skin Wound Care. 2020 Dec;33(12):1-5
pubmed: 33208633
J Am Soc Nephrol. 2006 Apr;17(4 Suppl 2):S148-52
pubmed: 16565241
J Nephrol. 2009 Mar-Apr;22(2):241-8
pubmed: 19384842
Toxins (Basel). 2018 Jan 08;10(1):
pubmed: 29316724
Ann Dermatol Venereol. 2003 Feb;130(2 Pt 1):187-90
pubmed: 12671581
Nephrol Dial Transplant. 2007 Nov;22(11):3268-72
pubmed: 17595180
Skin Therapy Lett. 2010 Feb;15(2):1-5
pubmed: 20361169
Int J Dermatol. 2010 Nov;49(11):1235-43
pubmed: 20964647
J Am Soc Nephrol. 1993 Nov;4(5):1205-13
pubmed: 8305648
Nephrol Dial Transplant. 2006 Mar;21(3):749-55
pubmed: 16249205
Acta Derm Venereol. 2001 May;81(2):108-11
pubmed: 11501646
Eur Heart J. 2008 May;29(9):1118-26
pubmed: 18390537
J Leukoc Biol. 2009 Jan;85(1):186-93
pubmed: 18840670
Nephrol Dial Transplant. 2006 Dec;21(12):3495-505
pubmed: 16968725
Acta Derm Venereol. 2009;89(3):236-44
pubmed: 19479118
Exp Dermatol. 2004 Jun;13(6):337-9
pubmed: 15186318